L-DOPA-13C

• Description:

  L-DOPA-13C is the 13C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

• UNSPSC:

  12352005

• Target:

  Dopamine Receptor; Endogenous Metabolite

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/l-dopa-13c.html

• Purity:

  98.0

• Solubility:

  0.1 M HCl : 20 mg/mL (ultrasonic; warming; adjust pH to pH to 2 with HCl)

• Smiles:

  O[13C]([C@@H](N)CC1=CC(O)=C(C=C1)O)=O

• Molecular Formula:

  C8 13CH11NO4

• Molecular Weight:

  198.18

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38 (12) :2405-10.|[3]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 200814 (4) :273-80. Epub 2007 Nov 7.|[4]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 310:237.|[5]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 154 (2) :330-5.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [586971-29-1]